Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Jun;112(2):429–434. doi: 10.1111/j.1476-5381.1994.tb13090.x

Benzodiazepine/cholecystokinin interactions at functional CCK receptors in rat brain.

P R Boden 1, G N Woodruff 1
PMCID: PMC1910342  PMID: 8075861

Abstract

1. The effects of benzodiazepines on cholecystokinin (CCK) responses produced following activation of CCKB receptors by pentagastrin in the ventromedial hypothalamus (VMH) or CCKA receptors by CCK-8S in the dorsal raphe of the rat brain in vitro have been investigated. 2. The benzodiazepine agonist, flurazepam, at high concentrations, blocked pentagastrin-induced excitations in the rat VMH yielding an equilibrium constant (Ke) value of 12.5 microM. 3. In the rat dorsal raphe, where activation of CCKA receptors leads to neuronal depolarization, flurazepam also produced a weak block of the CCK response. 4. Flurazepam blocked CCK responses but not carbachol-induced excitations of VMH neurones. The inhibition of CCK responses by flurazepam was not blocked by the benzodiazepine antagonist, flumazenil. 5. These data suggest that flurazepam is a weak antagonist at central CCKB receptors. 6. At central CCKA receptors, flurazepam blocked CCK-8S responses but the inhibition was not competitive, with a reduction in the peak CCK-8S obtainable in the presence of flurazepam. These results suggest that flurazepam acts at a site other than the CCKA receptor itself to block CCK responses in the dorsal raphe.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin H. A., File S. E. Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor. Brain Res Bull. 1988 May;20(5):603–606. doi: 10.1016/0361-9230(88)90219-5. [DOI] [PubMed] [Google Scholar]
  2. Boden P. R., Hill R. G. Effects of cholecystokinin and pentagastrin on rat hippocampal neurones maintained in vitro. Neuropeptides. 1988 Aug-Sep;12(2):95–103. doi: 10.1016/0143-4179(88)90037-6. [DOI] [PubMed] [Google Scholar]
  3. Boden P. R., Woodruff G. N., Pinnock R. D. Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain. Br J Pharmacol. 1991 Mar;102(3):635–638. doi: 10.1111/j.1476-5381.1991.tb12225.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boden P., Hill R. G. Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br J Pharmacol. 1988 May;94(1):246–252. doi: 10.1111/j.1476-5381.1988.tb11521.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bouthillier A., De Montigny C. Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat. Eur J Pharmacol. 1988 Jun 22;151(1):135–138. doi: 10.1016/0014-2999(88)90703-0. [DOI] [PubMed] [Google Scholar]
  6. Bradwejn J., de Montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature. 1984 Nov 22;312(5992):363–364. doi: 10.1038/312363a0. [DOI] [PubMed] [Google Scholar]
  7. Dodd J., Kelly J. S. The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res. 1981 Feb 2;205(2):337–350. doi: 10.1016/0006-8993(81)90344-9. [DOI] [PubMed] [Google Scholar]
  8. Dorow R., Horowski R., Paschelke G., Amin M. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet. 1983 Jul 9;2(8341):98–99. doi: 10.1016/s0140-6736(83)90076-4. [DOI] [PubMed] [Google Scholar]
  9. Harro J., Lang A., Vasar E. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol. 1990 May 3;180(1):77–83. doi: 10.1016/0014-2999(90)90594-v. [DOI] [PubMed] [Google Scholar]
  10. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci. 1993 Jun;14(6):244–249. doi: 10.1016/0165-6147(93)90020-k. [DOI] [PubMed] [Google Scholar]
  11. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728–6732. doi: 10.1073/pnas.87.17.6728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kubota K., Sugaya K., Matsuda I., Matsuoka Y., Terawaki Y. Reversal of antinociceptive effect of cholecystokinin by benzodiazepines and a benzodiazepine antagonist, Ro 15-1788. Jpn J Pharmacol. 1985 Jan;37(1):101–105. doi: 10.1254/jjp.37.101. [DOI] [PubMed] [Google Scholar]
  13. Kubota K., Sugaya K., Sunagane N., Matsuda I., Uruno T. Cholecystokinin antagonism by benzodiazepines in the contractile response of the isolated guinea-pig gallbladder. Eur J Pharmacol. 1985 Apr 2;110(2):225–231. doi: 10.1016/0014-2999(85)90215-8. [DOI] [PubMed] [Google Scholar]
  14. Little H. J. The benzodiazepines: anxiolytic and withdrawal effects. Neuropeptides. 1991 Jul;19 (Suppl):11–14. doi: 10.1016/0143-4179(91)90077-v. [DOI] [PubMed] [Google Scholar]
  15. Singh L., Field M. J., Hughes J., Menzies R., Oles R. J., Vass C. A., Woodruff G. N. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br J Pharmacol. 1991 Sep;104(1):239–245. doi: 10.1111/j.1476-5381.1991.tb12413.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989 Jun;46(6):511–517. doi: 10.1001/archpsyc.1989.01810060031006. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES